Bronchospasm News and Research

RSS
Dopamine may worsen lung inflammation in asthma

Dopamine may worsen lung inflammation in asthma

Study uncovers cause of asthmatic lung spasms

Study uncovers cause of asthmatic lung spasms

FDA approves new drug for treatment of lung disease caused by Mycobacterium avium complex

FDA approves new drug for treatment of lung disease caused by Mycobacterium avium complex

CHMP issues positive opinion supporting use of Trelegy Ellipta in broader group of COPD patients

CHMP issues positive opinion supporting use of Trelegy Ellipta in broader group of COPD patients

Study aims to investigate risk factors for PPCs in surgical patients with gastric cancer

Study aims to investigate risk factors for PPCs in surgical patients with gastric cancer

FDA recalls montelukast tablets by Camber Pharmaceuticals due to drug mix-up

FDA recalls montelukast tablets by Camber Pharmaceuticals due to drug mix-up

AstraZeneca’s new precision biologic gets FDA approval to treat severe eosinophilic asthma

AstraZeneca’s new precision biologic gets FDA approval to treat severe eosinophilic asthma

Pfizer receives FDA approval for new therapy to treat adults and children with AML

Pfizer receives FDA approval for new therapy to treat adults and children with AML

Pulmatrix announces positive results from Phase 1 study of novel dry powder formulation in COPD patients

Pulmatrix announces positive results from Phase 1 study of novel dry powder formulation in COPD patients

FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

Basaglar (insulin glargine injection) approved to improve glycemic control in diabetes patients

Basaglar (insulin glargine injection) approved to improve glycemic control in diabetes patients

New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

Takeda highlights safety, efficacy of vedolizumab for UC and CD at ACG Annual Scientific Meeting

Takeda highlights safety, efficacy of vedolizumab for UC and CD at ACG Annual Scientific Meeting

Tresiba and Ryzodeg approved to improve blood sugar control in adults with diabetes mellitus

Tresiba and Ryzodeg approved to improve blood sugar control in adults with diabetes mellitus

Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

STIOLTO RESPIMAT Inhalation Spray now available for treatment of COPD across the U.S.

STIOLTO RESPIMAT Inhalation Spray now available for treatment of COPD across the U.S.

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Alexza updates, amends ADASUVE (Staccato loxapine) commercial partnerships with Ferrer and Teva

Alexza updates, amends ADASUVE (Staccato loxapine) commercial partnerships with Ferrer and Teva

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC